PharmaResearch Future Growth

Future criteria checks 4/6

PharmaResearch is forecast to grow earnings and revenue by 20.5% and 13.9% per annum respectively. EPS is expected to grow by 19.6% per annum. Return on equity is forecast to be 20.3% in 3 years.

Key information

20.5%

Earnings growth rate

19.6%

EPS growth rate

Biotechs earnings growth	44.7%
Revenue growth rate	13.9%
Future return on equity	20.3%
Analyst coverage	Low
Last updated	23 Feb 2024

Recent future growth updates

Recent updates

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Apr 09

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Mar 05

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Feb 17

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Feb 02

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Jan 20

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Jan 07

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Dec 23

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Nov 25

Earnings and Revenue Growth Forecasts

KOSDAQ:A214450 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	345,767	116,667	100,750	121,100	3
12/31/2024	304,467	100,133	50,300	103,667	3
12/31/2023	261,011	76,551	52,260	64,945	N/A
9/30/2023	244,661	64,902	41,817	53,239	N/A
6/30/2023	222,030	55,615	43,861	57,280	N/A
3/31/2023	204,932	48,964	46,461	61,734	N/A
12/31/2022	194,759	40,577	41,686	59,404	N/A
9/30/2022	183,191	46,501	43,484	65,744	N/A
6/30/2022	175,719	42,366	42,071	65,573	N/A
3/31/2022	164,813	43,752	38,455	62,868	N/A
12/31/2021	154,083	46,689	41,866	65,297	N/A
9/30/2021	143,282	47,110	36,738	58,386	N/A
6/30/2021	133,706	41,534	7,076	45,944	N/A
3/31/2021	122,609	40,153	6,042	43,936	N/A
12/31/2020	108,746	32,774	-2,991	32,392	N/A
9/30/2020	101,282	27,003	-4,928	27,003	N/A
6/30/2020	91,747	23,109	13,967	23,521	N/A
3/31/2020	84,091	16,407	11,603	18,946	N/A
12/31/2019	83,872	16,667	9,489	19,272	N/A
9/30/2019	77,416	19,060	250	12,948	N/A
6/30/2019	73,324	16,384	-7,794	13,176	N/A
3/31/2019	70,242	15,310	-12,069	8,818	N/A
12/31/2018	64,281	14,408	-19,414	5,203	N/A
9/30/2018	61,865	6,913	-13,353	6,975	N/A
6/30/2018	60,777	11,134	-9,967	7,070	N/A
3/31/2018	56,519	12,579	-9,865	5,562	N/A
12/31/2017	54,470	12,956	833	8,555	N/A
9/30/2017	50,615	14,522	N/A	8,312	N/A
6/30/2017	47,241	13,472	N/A	6,052	N/A
3/31/2017	46,580	14,378	N/A	7,680	N/A
12/31/2016	45,953	13,909	N/A	8,161	N/A
9/30/2016	45,092	16,725	N/A	10,507	N/A
12/31/2015	37,455	12,878	N/A	16,023	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A214450's forecast earnings growth (20.5% per year) is above the savings rate (2.5%).

Earnings vs Market: A214450's earnings (20.5% per year) are forecast to grow slower than the KR market (28.3% per year).

High Growth Earnings: A214450's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A214450's revenue (13.9% per year) is forecast to grow faster than the KR market (9.2% per year).

High Growth Revenue: A214450's revenue (13.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A214450's Return on Equity is forecast to be high in 3 years time (20.3%)

PharmaResearch Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target increased by 19% to ₩158,750

Price target increased by 11% to ₩107,500

Price target decreased to ₩88,300

Consensus forecasts updated

Price target decreased to ₩96,500

Price target decreased to ₩100,000

Recent updates

Investor sentiment improves as stock rises 18%

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Full year 2023 earnings released: EPS: ₩7,571 (vs ₩4,067 in FY 2022)

Upcoming dividend of ₩660 per share at 0.6% yield

Price target increased by 19% to ₩158,750

Investor sentiment improves as stock rises 15%

Now 20% undervalued

New minor risk - Shareholder dilution

Now 20% undervalued

Price target increased by 11% to ₩107,500

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 20%

Now 21% undervalued

Price target decreased to ₩88,300

Upcoming dividend of ₩600 per share

Consensus forecasts updated

Price target decreased to ₩96,500

Price target decreased to ₩100,000

Consensus forecasts updated

Price target increased to ₩112,500

Upcoming dividend of ₩500 per share

PharmaResearch Co., Ltd. (KOSDAQ:A214450) acquired Medicoson Co., Ltd.

Price target increased to ₩120,000

Consensus revenue estimates increase to ₩152.8m

Price target increased to ₩88,100

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

New 90-day high: ₩64,900

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

New 90-day low: ₩53,900

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

New 90-day low: ₩56,100

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

New 90-day low: ₩57,600

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Third quarter 2020 earnings released: EPS ₩812

Price target raised to ₩78,433

New 90-day high - ₩63,300

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies